Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders.
Whereas beta-2-microglobulin (beta2M) has mainly been used as a prognostic factor in patients with lymphoproliferative disorders, some studies have reported the value of beta2M in myeloproliferative disorders (MPD). In order to investigate a potential role in the pathogenesis of MPD and to find a possible value as indicators in monitoring the course of the disease, we measured beta2M, TNF-alpha, IL-1alpha, IL-1beta, IL-2, sIL-2R, IL-6 and IL-10 in 55 patients with MPD, at diagnosis and during the course of the disease. In progressive disease and particularly when transformation to acute leukemia occurred, high levels of beta2M, IL-2 and sIL-2R were found in all patients; the elevation was progressive, which suggests a potential prognostic usefulness in the individual patient.
Bourantas
K L
KL
Department of Internal Medicine, University of Ioannina Medical School, Anatoli, Greece.
Hatzimichael
E C
EC
Makis
A C
AC
Chaidos
A
A
Kapsali
E D
ED
Tsiara
S
S
Mavridis
A
A
D000368:Aged; D014408:Biomarkers, Tumor; D018450:Disease Progression; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007378:Interleukins / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D001613:beta 2-Microglobulin / Q000032:analysis*
D014408:Biomarkers, Tumor; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D001613:beta 2-Microglobulin